71 related articles for article (PubMed ID: 8757193)
1. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin.
Roy DC; Ouellet S; Le Houillier C; Ariniello PD; Perreault C; Lambert JM
J Natl Cancer Inst; 1996 Aug; 88(16):1136-45. PubMed ID: 8757193
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer.
Derbyshire EJ; Stahel RA; Wawrzynczak EJ
Cancer Immunol Immunother; 1992; 35(6):417-20. PubMed ID: 1327529
[TBL] [Abstract][Full Text] [Related]
3. A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells.
Krueger P; Nitz C; Foster R; MacDonald C; Gelber O; Lalehzadeh G; Goodson R; Winter J; Gelber C
Cancer Immunol Immunother; 2003 Jun; 52(6):367-77. PubMed ID: 12669243
[TBL] [Abstract][Full Text] [Related]
4. Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.
Brusa P; Pietribiasi F; Bussolati G; Dosio F; Arione R; Comoglio PM; Prat M; Cattel L
Cancer Immunol Immunother; 1989; 29(3):185-92. PubMed ID: 2659170
[TBL] [Abstract][Full Text] [Related]
5. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
6. Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cells.
Levin LV; Griffin TW; Childs LR; Davis S; Haagensen DE
Cancer Immunol Immunother; 1987; 24(3):202-6. PubMed ID: 3496151
[TBL] [Abstract][Full Text] [Related]
7. In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain.
Rostaing-Capaillon O; Casellas P
Cancer Immunol Immunother; 1991; 34(1):24-30. PubMed ID: 1722138
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins.
Vooijs WC; Post J; Wijdenes J; Schuurman HJ; Bolognesi A; Polito L; Stirpe F; Bast EJ; de Gast GC
Cancer Immunol Immunother; 1996 Jul; 42(6):319-28. PubMed ID: 8830734
[TBL] [Abstract][Full Text] [Related]
9. Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.
Rasmussen RA; Counts SL; Lambert JM; Collinson AR
Cancer Immunol Immunother; 1992; 35(5):355-63. PubMed ID: 1394340
[TBL] [Abstract][Full Text] [Related]
10. Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice.
Brusa P; Dosio F; Pietribiasi F; Delprino L; Feraiorni P; Mariani M; Bussolati G; Cattel L
Cancer Immunol Immunother; 1992; 35(6):373-80. PubMed ID: 1394342
[TBL] [Abstract][Full Text] [Related]
11. Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells.
Froesch BA; Stahel RA; Zangemeister-Wittke U
Cancer Immunol Immunother; 1996 Jan; 42(1):55-63. PubMed ID: 8625367
[TBL] [Abstract][Full Text] [Related]
12. Response of primary human mammary tumor cell cultures to a monoclonal antibody-recombinant ricin A chain immunotoxin.
Bjorn MJ; Smith HS; Dairkee SH
Cancer Immunol Immunother; 1988; 26(2):121-4. PubMed ID: 3258792
[TBL] [Abstract][Full Text] [Related]
13. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications.
Shin YK; Choi YL; Choi EY; Kim MK; Kook MC; Chung J; Choi YK; Kim HS; Song HG; Park SH
Cancer Immunol Immunother; 2003 Aug; 52(8):506-12. PubMed ID: 12768327
[TBL] [Abstract][Full Text] [Related]
14. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.
Furman RR; Grossbard ML; Johnson JL; Pecora AL; Cassileth PA; Jung SH; Peterson BA; Nadler LM; Freedman A; Bayer RL; Bartlett NL; Hurd DD; Cheson BD; ;
Leuk Lymphoma; 2011 Apr; 52(4):587-96. PubMed ID: 21275630
[TBL] [Abstract][Full Text] [Related]
15. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
Mathew M; Verma RS
Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
[TBL] [Abstract][Full Text] [Related]
16. Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.
Cattel L; Delprino L; Brusa P; Dosio F; Comoglio PM; Prat M
Cancer Immunol Immunother; 1988; 27(3):233-40. PubMed ID: 3263208
[TBL] [Abstract][Full Text] [Related]
17. Expression of markers shared between human natural killer cells and neuroblastoma lines.
McGarry RC; Pinto A; Hammersley-Straw DR; Trevenen CL
Cancer Immunol Immunother; 1988; 27(1):47-52. PubMed ID: 2456146
[TBL] [Abstract][Full Text] [Related]
18. In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma.
Webb KS; Liberman SN; Ware JL; Walther PJ
Cancer Immunol Immunother; 1986; 21(2):100-6. PubMed ID: 2418949
[TBL] [Abstract][Full Text] [Related]
19. An ineffective monoclonal antibody-ricin A chain conjugate is converted to a tumouricidal agent in vivo by subsequent systemic administration of ricin B chain.
Eccles SA; McIntosh DP; Purvies HP; Cumber AJ; Parnell GD; Forrester JA; Styles JM; Dean CJ
Cancer Immunol Immunother; 1987; 24(1):37-41. PubMed ID: 3493071
[TBL] [Abstract][Full Text] [Related]
20. Two monoclonal antibodies against small-cell lung cancer show existence of synergism in binding.
Saito S; Inoue T; Kawase I; Hara H; Tanio Y; Tachibana I; Hayashi S; Watanabe M; Matsunashi M; Osaki T
Cancer Immunol Immunother; 1991; 33(3):165-70. PubMed ID: 1646075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
